Example of American Journal of Cardiovascular Drugs format
Recent searches

Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format Example of American Journal of Cardiovascular Drugs format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

American Journal of Cardiovascular Drugs — Template for authors

Publisher: Springer
Categories Rank Trend in last 3 yrs
Cardiology and Cardiovascular Medicine #68 of 317 -
Pharmacology (medical) #64 of 246 down down by 12 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 197 Published Papers | 1008 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 11/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access

SAGE

Quality:  
High
CiteRatio: 4.8
SJR: 1.164
SNIP: 1.22
open access Open Access

Springer

Quality:  
High
CiteRatio: 6.5
SJR: 1.108
SNIP: 1.077
open access Open Access

SAGE

Quality:  
Good
CiteRatio: 4.3
SJR: 0.787
SNIP: 0.865
open access Open Access

Wiley

Quality:  
Good
CiteRatio: 4.2
SJR: 0.818
SNIP: 0.742

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

2.674

4% from 2018

Impact factor for American Journal of Cardiovascular Drugs from 2016 - 2019
Year Value
2019 2.674
2018 2.578
2017 2.643
2016 2.768
graph view Graph view
table view Table view

5.1

9% from 2019

CiteRatio for American Journal of Cardiovascular Drugs from 2016 - 2020
Year Value
2020 5.1
2019 4.7
2018 4.6
2017 5.4
2016 4.7
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has increased by 4% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 9% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

1.063

24% from 2019

SJR for American Journal of Cardiovascular Drugs from 2016 - 2020
Year Value
2020 1.063
2019 0.854
2018 0.903
2017 0.951
2016 0.927
graph view Graph view
table view Table view

0.959

16% from 2019

SNIP for American Journal of Cardiovascular Drugs from 2016 - 2020
Year Value
2020 0.959
2019 0.824
2018 0.853
2017 1.029
2016 0.921
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has increased by 24% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 16% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

American Journal of Cardiovascular Drugs

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Springer

American Journal of Cardiovascular Drugs

American Journal of Cardiovascular Drugs - The ultimate guide to prevention and management of cardiovascular disease. Promoting rational therapy and effective patient management within the discipline of cardiology, the journal covers all aspects of the management of cardiovasc...... Read More

Medicine

i
Last updated on
11 Jul 2020
i
ISSN
1175-3277
i
Impact Factor
Medium - 0.886
i
Acceptance Rate
60%
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Green faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
SPBASIC
i
Citation Type
Author Year
(Blonder et al, 1982)
i
Bibliography Example
Beenakker CWJ (2006) Specular andreev reflection in graphene. Phys Rev Lett 97(6):067,007, URL 10.1103/PhysRevLett.97.067007

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.2165/0129784-200808060-00004
Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism
Beatrice A. Golomb1, Marcella A. Evans2, Marcella A. Evans1

Abstract:

HMG-CoA reductase inhibitors (statins) are a widely used class of drug, and like all medications, have potential for adverse effects (AEs). Here we review the statin AE literature, first focusing on muscle AEs as the most reported problem both in the literature and by patients. Evidence regarding the statin muscle AE mechanis... HMG-CoA reductase inhibitors (statins) are a widely used class of drug, and like all medications, have potential for adverse effects (AEs). Here we review the statin AE literature, first focusing on muscle AEs as the most reported problem both in the literature and by patients. Evidence regarding the statin muscle AE mechanism, dose effect, drug interactions, and genetic predisposition is examined. We hypothesize, and provide evidence, that the demonstrated mitochondrial mechanisms for muscle AEs have implications to other nonmuscle AEs in patients treated with statins. In meta-analyses of randomized controlled trials (RCTs), muscle AEs are more frequent with statins than with placebo. A number of manifestations of muscle AEs have been reported, with rhabdomyolysis the most feared. AEs are dose dependent, and risk is amplified by drug interactions that functionally increase statin potency, often through inhibition of the cytochrome P450 3A4 system. An array of additional risk factors for statin AEs are those that amplify (or reflect) mitochondrial or metabolic vulnerability, such as metabolic syndrome factors, thyroid disease, and genetic mutations linked to mitochondrial dysfunction. Converging evidence supports a mitochondrial foundation for muscle AEs associated with statins, and both theoretical and empirical considerations suggest that mitochondrial dysfunction may also underlie many nonmuscle statin AEs. Evidence from RCTs and studies of other designs indicates existence of additional statin-associated AEs, such as cognitive loss, neuropathy, pancreatic and hepatic dysfunction, and sexual dysfunction. Physician awareness of statin AEs is reportedly low even for the AEs most widely reported by patients. Awareness and vigilance for AEs should be maintained to enable informed treatment decisions, treatment modification if appropriate, improved quality of patient care, and reduced patient morbidity. read more read less

Topics:

Statin (53%)53% related to the paper
View PDF
599 Citations
Journal Article DOI: 10.2165/1153161-S0-000000000-00000
Markers of inflammation and cardiovascular disease: clinical applications of C-reactive protein determination.

Abstract:

C-reactive protein (CRP) is produced by the macrophages in the liver and adipocytes and is integrated in the acute-phase response pathway. Being a nonspecific marker of inflammation, it increases in response to inflammation. The results of recent studies that have analyzed the role of CRP have not yet influenced current clini... C-reactive protein (CRP) is produced by the macrophages in the liver and adipocytes and is integrated in the acute-phase response pathway. Being a nonspecific marker of inflammation, it increases in response to inflammation. The results of recent studies that have analyzed the role of CRP have not yet influenced current clinical practice. When used in combination with other established biomarkers for the prediction of the first major cardiovascular event or death, CRP does not improve the risk stratification obtained with the current guidelines. The reduction of CRP levels itself or as a statin-related pleiotropic effect has been assessed in different scenarios, including the acute phase of myocardial infarction; secondary prevention of cardiovascular diseases; special patient populations, such as diabetic patients; and finally in a primary prevention study (JUPITER [Justification for the Use of statins in primary Prevention: an Intervention Trial Evaluating Rosuvastatin]). Risk stratification in all the examined scenarios was related to serum LDL-C levels; in other words, the degree of cardiovascular risk was always lipid dependent. read more read less

Topics:

C-reactive protein (57%)57% related to the paper, Rosuvastatin (55%)55% related to the paper, Statin (53%)53% related to the paper
334 Citations
Journal Article DOI: 10.2165/00129784-200404050-00002
Interactions Between Grapefruit Juice and Cardiovascular Drugs
David G. Bailey1, David G. Bailey2, George K. Dresser2

Abstract:

Grapefruit juice can alter oral drug pharmacokinetics by different mechanisms. Irreversible inactivation of intestinal cytochrome P450 (CYP) 3A4 is produced by commercial grapefruit juice given as a single normal amount (e. g. 200–300mL) or by whole fresh fruit segments. As a result, presystemic metabolism is reduced and oral... Grapefruit juice can alter oral drug pharmacokinetics by different mechanisms. Irreversible inactivation of intestinal cytochrome P450 (CYP) 3A4 is produced by commercial grapefruit juice given as a single normal amount (e. g. 200–300mL) or by whole fresh fruit segments. As a result, presystemic metabolism is reduced and oral drug bioavailability increased. Enhanced oral drug bioavailability can occur 24 hours after juice consumption. Inhibition of P-glycoprotein (P-gp) is a possible mechanism that increases oral drug bioavailability by reducing intestinal and/or hepatic efflux transport. Recently, inhibition of organic anion transporting polypeptides by grapefruit juice was observed in vitro; intestinal uptake transport appeared decreased as oral drug bioavailability was reduced. read more read less

Topics:

Grapefruit juice (74%)74% related to the paper, Bioavailability (59%)59% related to the paper, Pharmacokinetics (51%)51% related to the paper, Cytochrome P450 (51%)51% related to the paper
221 Citations
Journal Article DOI: 10.2165/00129784-200707030-00004
Endogenous and Exogenous Cardiac Glycosides and their Mechanisms of Action
Wilhelm Schoner1, Georgios Scheiner-Bobis1

Abstract:

Cardiac glycosides have been used for decades to treat congestive heart failure The recent identification of cardiotonic steroids such as ouabain, digoxin, marinobufagenin, and telocinobufagin in blood plasma, adrenal glands, and hypothalamus of mammals led to exciting new perspectives in the pathology of heart failure and ar... Cardiac glycosides have been used for decades to treat congestive heart failure The recent identification of cardiotonic steroids such as ouabain, digoxin, marinobufagenin, and telocinobufagin in blood plasma, adrenal glands, and hypothalamus of mammals led to exciting new perspectives in the pathology of heart failure and arterial hypertension Biosynthesis of ouabain and digoxin occurs in adrenal glands and is under the control of angiotensin II, endothelin, and epinephrine released from cells of the midbrain upon stimulation of brain areas sensing cerebrospinal Na(+) concentration and, apparently, the body's K(+) content Rapid changes of endogenous ouabain upon physical exercise may favor the economy of the heart by a rise of intracellular Ca(2)(+) levels in cardiac and atrial muscle cells According to the sodium pump lag hypothesis, this may be accomplished by partial inhibition of the sodium pump and Ca(2+) influx via the Na(+)/Ca(2+) exchanger working in reverse mode or via activation of the Na(+)/K(+)-ATPase signalosome complex, generating intracellular calcium oscillations, reactive oxygen species, and gene activation via nuclear factor-kappaB or extracellular signal-regulated kinases 1 and 2 Elevated concentrations of endogenous ouabain and marinobufagenin in the subnanomolar concentration range were found to stimulate proliferation and differentiation of cardiac and smooth muscle cells They may have a primary role in the development of cardiac dysfunction and failure because (i) offspring of hypertensive patients evidently inherit elevated plasma concentrations of endogenous ouabain; (ii) such elevated concentrations correlate positively with cardiac dysfunction, hypertrophy, and arterial hypertension; (iii) about 40% of Europeans with uncomplicated essential hypertension show increased concentrations of endogenous ouabain associated with reduced heart rate and cardiac hypertrophy; (iv) in patients with advanced arterial hypertension, circulating levels of endogenous ouabain correlate with BP and total peripheral resistance; (v) among patients with idiopathic dilated cardiomyopathy, high circulating levels of endogenous ouabain and marinobufagenin identify those individuals who are predisposed to progressing more rapidly to heart failure, suggesting that endogenous ouabain (and marinobufagenin) may contribute to toxicity upon digoxin therapy In contrast to endogenous ouabain, endogenous marinobufagenin may act as a natriuretic substance as well It shows a higher affinity for the ouabain-insensitive alpha(1) isoform of Na(+)/K(+)-ATPase of rat kidney tubular cells and its levels are increased in volume expansion and pre-eclampsia Digoxin, which is synthesized in adrenal glands, seems to counteract the hypertensinogenic action of ouabain in rats, as do antibodies against ouabain, for example, (Digibind) and rostafuroxin (PST 2238), a selective ouabain antagonist It lowers BP in ouabain- and adducin-dependent hypertension in rats and is a promising new class of antihypertensive medication in humans read more read less

Topics:

Ouabain (68%)68% related to the paper, Marinobufagenin (59%)59% related to the paper, Digoxin (53%)53% related to the paper, Essential hypertension (53%)53% related to the paper, Idiopathic dilated cardiomyopathy (53%)53% related to the paper
192 Citations
open accessOpen access Journal Article DOI: 10.1007/S40256-013-0029-0
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.

Abstract:

Background Edoxaban, an oral direct factor Xa inhibitor, is in development for thromboprophylaxis, including prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). P-glycoprotein (P-gp), an efflux transporter, modulates absorption and excretion of xenobiotics. Edoxaban is a P-gp substrate, and ... Background Edoxaban, an oral direct factor Xa inhibitor, is in development for thromboprophylaxis, including prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). P-glycoprotein (P-gp), an efflux transporter, modulates absorption and excretion of xenobiotics. Edoxaban is a P-gp substrate, and several cardiovascular (CV) drugs have the potential to inhibit P-gp and increase drug exposure. read more read less

Topics:

Edoxaban (63%)63% related to the paper, Factor Xa Inhibitor (61%)61% related to the paper, Cardiovascular agent (55%)55% related to the paper, Pharmacokinetics (51%)51% related to the paper, Drug (50%)50% related to the paper
View PDF
192 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for American Journal of Cardiovascular Drugs.

It automatically formats your research paper to Springer formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

American Journal of Cardiovascular Drugs format uses SPBASIC citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write American Journal of Cardiovascular Drugs in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the American Journal of Cardiovascular Drugs guidelines and auto format it.

2. Do you follow the American Journal of Cardiovascular Drugs guidelines?

Yes, the template is compliant with the American Journal of Cardiovascular Drugs guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in American Journal of Cardiovascular Drugs?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the American Journal of Cardiovascular Drugs citation style.

4. Can I use the American Journal of Cardiovascular Drugs templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for American Journal of Cardiovascular Drugs.

5. Can I use a manuscript in American Journal of Cardiovascular Drugs that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper American Journal of Cardiovascular Drugs that you can download at the end.

6. How long does it usually take you to format my papers in American Journal of Cardiovascular Drugs?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in American Journal of Cardiovascular Drugs.

7. Where can I find the template for the American Journal of Cardiovascular Drugs?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per American Journal of Cardiovascular Drugs's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the American Journal of Cardiovascular Drugs's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. American Journal of Cardiovascular Drugs an online tool or is there a desktop version?

SciSpace's American Journal of Cardiovascular Drugs is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like American Journal of Cardiovascular Drugs?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like American Journal of Cardiovascular Drugs?”

11. What is the output that I would get after using American Journal of Cardiovascular Drugs?

After writing your paper autoformatting in American Journal of Cardiovascular Drugs, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is American Journal of Cardiovascular Drugs's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for American Journal of Cardiovascular Drugs?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for American Journal of Cardiovascular Drugs. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In American Journal of Cardiovascular Drugs?

The 5 most common citation types in order of usage for American Journal of Cardiovascular Drugs are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the American Journal of Cardiovascular Drugs?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per American Journal of Cardiovascular Drugs's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download American Journal of Cardiovascular Drugs in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in American Journal of Cardiovascular Drugs Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to American Journal of Cardiovascular Drugs formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template